Exelixis Rating Reiterated by Leerink Swann (EXEL)
May 2nd, 2014 - 0 comments - Filed Under - by Micah Haroldson
Filed Under: Analyst Articles - US - Investing
Exelixis (NASDAQ:EXEL)‘s stock had its “market perform” rating reiterated by research analysts at Leerink Swann in a report released on Friday, StockRatingsNetwork reports. They currently have a $4.50 price objective on the stock. Leerink Swann’s price target would suggest a potential upside of 27.84% from the company’s current price.
A number of other analysts have also recently weighed in on EXEL. Analysts at Jefferies Group reiterated a “hold” rating on shares of Exelixis in a research note on Friday. They now have a $4.00 price target on the stock. Separately, analysts at Credit Suisse cut their price target on shares of Exelixis from $6.00 to $5.00
Actually, just false information posted yet again by bashers. Swann did not post anything today -- LOL. You just like to make up numbers -- LOL. This is the most recent upgrade:
Piper Jaffray believes it's time to buy shares of Exelixis with the stock down 56% from the close on March 25. Piper thinks shares at current levels have "washed out" cabozantinib in castration-resistant prostate cancer. It reiterates an Overweight rating on Exelixis with an $11 price target.